Publications

Boomershine CS, Chamberlain A, Kendall P, Afshar-Sharif A-R, Huang H, Washington MK, Lawson WE, Thomas JW, Blackwell TS, Bhowmick NA. Autoimmune pancreatitis can result from loss of TGF-ß signaling in S100A4-positive dendritic cells. Gut. 2009;58:1267-1274.

A knockout of TGF-β signaling in dendritic cells resulted in the development of the first autoimmune pancreatitis mouse model and rationalizes the need for a more specific inducible conditional Tgfbr2 knockout mouse model.

Martinez-Ferrer M, Afshar-Sharif A-R, Uwamariya C, de Crombrugghe B, Davidson JM, Bhowmick NA. Dermal transforming growth factor-ß responsiveness mediates skin wound contraction and epithelial closure. Amer J Pathol. 2010;176:98-107.

This study describes how the dermal TGF-β is critical to skin epithelial wound closure. The absence of TGF-ß signaling in dermal fibroblasts, as found in embryonic tissues, is associated with accelerated re-epithelialization.z

Kiskowski MA, Jackson RS 2nd, Banerjee J, Li X, Kang M, Iturregui JM, Franco OE, Hayward SW, Bhowmick NA. Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res. 2011;71:3459-3470.

Here, hybrid mathematic modeling of tumor-epithelial interactions supported the biologic observations of the requirement of stromal heterogeneity in prostate cancer progression.

Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One. 2011;6:e22486.

This nested case control trial study illustrated that folate metabolism detected in blood and urine can predict prostate cancer recurrence following prostatectomy.

Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan K-H, Li X, Zhou H-M, Bhowmick NA. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS One. 2011;6:e27529.

This work demonstrated that YAP signaling in head and neck cancer,while associated with high-grade disease, is not a critical factor of epithelial to mesenchymal transdifferentiation.

Li X, Sterling JA, Fan F, Vessella RL, Shyr Y, Hayward SW, Matrisian LM, Bhowmick NA. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res. 2012;4:494-503. (cover)

This study demonstrated that paracrine signals at the primary prostate tumor site can mediate cancer survival and growth at the bone metastatic site.

Jackson RS 2nd, Placzek W, Fernandez A, Ziaee S, Chu C-Y, Stebbins J, Kitada S, Fritz G, Reed JC, Chung LW, Pellecchia M, Bhowmick NA. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia. 2012;14:656-665.

A novel transgenic mouse model and xenograft models of localized and bone metastatic prostate cancer were used to demonstrate that a small molecule Bcl2/Mcl1 antagonist could be an effective treatment for castrate resistant and tamoxifen resistant prostate cancer.